Lupin forays into Brazil by buying Medquimica

Lupin has forayed into the high growth Brazilian market by acquiring 100% equity stake in Medquimica Industria Farmaceutica SA. The deal is expected to shore up Lupin’s position in the Latin American pharmaceuticals market given the company’s acquisition of Laboratorios Grin in Mexico last fiscal.
 
Brazil’s pharmaceutical market has nearly doubled in size from 2009-2013, expanding at a CAGR of 17%, driven by growing public health expenditure and increasing household income. In 2013, retail drug sales reached a value of BRL 58 billion ($ 25.9 billion), making Brazil the sixth largest market in the world, accounting for 3.98% of global sales (based on ex-factory prices, taxes included, no discounts).
 
Incorporated in 1975, Medquimica is a broad based pharmaceutical company engaged in the development, manufacturing & commercialisation of branded generics, pure generics and OTC products. Medquimica is one of the fastest growing companies in the Brazilian branded generics market and a trusted brand with the distribution channel in Brazil. Medquimica recorded net revenues of approximately BRL 94 million (approximately $ 31 million) in calendar year 2014 and has over 550 employees.
 
Vinita Gupta, chief executive officer, Lupin Limited, said, “There are a lot of synergies to the acquisition and Lupin would not only leverage its research & technology strengths to build a high quality product pipeline but also use Medquimica’s commercial presence to expand business by targeting niche high-growth therapy segments. The acquisition is also a reflection of Lupin’s commitment to expand into the Latin American market and an important part of Lupin’s emerging markets play going forward.”